Linerixibat - GSK
Alternative Names: GSK 2330672; GSK 672Latest Information Update: 01 Sep 2025
At a glance
- Originator GlaxoSmithKline
- Developer GSK
- Class Antihyperglycaemics; Antipruritics; Benzene derivatives; Carboxylic acids; Ethers; Small molecules; Thiazepines
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Pruritus
- Phase II Primary biliary cirrhosis; Type 2 diabetes mellitus
- No development reported Cholestasis